Key result
Rose angina symptoms linked to up to ~98% higher 23-year CHD mortality in adults without known CHD.
Why the study?
Does the presence of Rose angina symptoms predict long-term CHD mortality in adults aged 40-49 years without known CHD?
Cohort (n=32,881)
Yes
Does the presence of Rose angina symptoms predict long-term CHD mortality in adults aged 40-49 years without known CHD?
Effect estimate: HR 1.50 (men) and HR 1.98 (women) (95% CI 1.16-1.93 (men) and 1.30-3.02 (women))
Angina symptoms identified by a short Rose Angina Questionnaire in adults aged 40-49 years without known CHD are associated with significantly elevated long-term CHD mortality.
Rose angina at ages 40–49 signals higher long-term CHD mortality risk; leaves open whether questionnaire-based screening improves outcomes in contemporary cohorts.
OBJECTIVE: To determine the long-term coronary heart disease (CHD) mortality in women and men with symptoms, according to the Rose Angina Questionnaire at a relatively young age. DESIGN: Cohort study with the baseline survey conducted during 1974-8. Information on symptoms was collected by a short, three-item version of the Rose Angina Questionnaire. Participants were re-invited to a similar survey five years later and followed for mortality throughout 2000. SETTING: Three counties in Norway (the Norwegian Counties Study). PARTICIPANTS: 16 616 men and 16 265 women aged 40-49 years and denying CHD in 1974-8. MAIN OUTCOME MEASURE: CHD mortality during 23 years. RESULTS: By the end of follow-up 1316 men (7.9%) and 310 women (1.9%) had died from CHD, including 16% (66/406) of men and 4% (24/563) of women with Rose angina in 1974-8. Rose angina implied an elevated mortality from CHD with adjusted hazard ratios 1.50 (95% CI 1.16 to 1.93) in men and 1.98 (95% CI 1.30 to 3.02) in women. According to calculations based on the Cox model these increases in risk are similar to those associated with elevations of total cholesterol by 1.8 mmol/l (men) and 2.5 mmol/l (women) or elevations of systolic blood pressure by 21 mm Hg (men) or 31 mm Hg (women). CONCLUSIONS: Angina symptoms in ages as low as 40-49 years were associated with elevated long-term CHD mortality in Norwegian women and men. This indicates that the three-item version of the Rose Angina Questionnaire, although a screening tool rather than a diagnostic test, adds information on undiagnosed CHD in both sexes.
No takes yet. Share an insight, caveat, or question.
Graff‐Iversen et al. (2007) conducted a cohort in Coronary heart disease (n=32,881). Rose angina symptoms vs. No Rose angina symptoms was evaluated on CHD mortality (HR 1.50 (men) and HR 1.98 (women), 95% CI 1.16-1.93 (men) and 1.30-3.02 (women)). Rose angina symptoms in adults aged 40-49 years without known CHD were associated with increased 23-year CHD mortality in men (HR 1.50; 95% CI 1.16-1.93) and women (HR 1.98; 95% CI 1.30-3.02).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: